Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials

References

• El-SeragHBHepatocellular carcinomaN Engl J Med2011365121118112721992124
   PubMed Web of Science ®Google Scholar
• BoschFXRibesJBorràsJEpidemiology of primary liver cancerSemin Liver Dis199919327128510518307
   PubMed Web of Science ®Google Scholar
• El-SeragHBMasonACRising incidence of hepatocellular carcinoma in the United StatesN Engl J Med19993401074575010072408
   PubMed Web of Science ®Google Scholar
• LencioniRManagement of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapyCrit Rev Oncol Hematol201283221622422142656
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialJ Clin Oncol201331324067407524081937
   PubMed Web of Science ®Google Scholar
• JohnsonPJQinSParkJWBrivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyJ Clin Oncol201331283517352423980084
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTLinifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialJ Clin Oncol201533217217925488963
   PubMed Web of Science ®Google Scholar
• ChengALThongprasertSLimHYRandomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaHepatology201664377478427082062
   PubMed Web of Science ®Google Scholar
• KudoMFinnRSQinSLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialLancet2018391101261163117329433850
   PubMed Web of Science ®Google Scholar
• PalmerDHMaYTPeck-RadosavljevicMA multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinomaBr J Cancer201811891162116829563636
   PubMed Web of Science ®Google Scholar
• PinterMSieghartWGraziadeiISorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosisOncologist2009141707619144684
   PubMed Web of Science ®Google Scholar
• VilgrainVPereiraHAssenatEEfficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialLancet Oncol201718121624163629107679
   PubMed Web of Science ®Google Scholar
• ChowPKGandhiMTanSBSIRVENIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinomaJ Clin Oncol201836191913192129498924
   PubMed Web of Science ®Google Scholar
• ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med19981724281528349921604
   PubMed Web of Science ®Google Scholar
• ShaoYYShauWYChanSYLuLCHsuCHChengALTreatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trialsOncology201588634535225572912
   PubMed Web of Science ®Google Scholar
• GebskiVGibbsEGandhiMVESPRO: an individual patient data prospective meta-analysis of selective internal radiation therapy versus sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRVENIB TrialsJMIR Res Protoc201762e1728202430
   PubMed Web of Science ®Google Scholar
• JacksonRPsarelliEEBerhaneSKhanHJohnsonPImpact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trialsJ Clin Oncol201735662262828045619
   PubMed Web of Science ®Google Scholar
• KudoMHanGFinnRSBrivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trialHepatology20146051697170724996197
   PubMed Web of Science ®Google Scholar
• LlovetJMDecaensTRaoulJLBrivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJ Clin Oncol201331283509351623980090
   PubMed Web of Science ®Google Scholar
• RimassaLSantoroADanieleBTivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centersTumori2015101213914325838254
   PubMed Web of Science ®Google Scholar
• PeixotoRDRenoufDJGillSCheungWYLimHJRelationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinomaJ Gastrointest Oncol20145425926425083298
   PubMedGoogle Scholar
• AokiHHayashiJMoriyamaMArakawaYHinoOHepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1J Virol20007441736174110644344
   PubMed Web of Science ®Google Scholar
• BürckstümmerTKriegsMLupbergerJPauliEKSchmittelSHildtERaf-1 kinase associates with hepatitis C virus NS5A and regulates viral replicationFEBS Lett2006580257558016405965
   PubMed Web of Science ®Google Scholar
• GiambartolomeiSCovoneFLevreroMBalsanoCSustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core proteinOncogene200120202606261011420671
   PubMed Web of Science ®Google Scholar
• SchmitzKJWohlschlaegerJLangHActivation of the ERK and Akt signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infectionJ Hepatol2008481839017998146
   PubMed Web of Science ®Google Scholar
• MeyerTTreatment of advanced hepatocellular carcinoma: beyond sorafenibLancet Gastroenterol Hepatol20183421822029533189
   PubMed Web of Science ®Google Scholar
• LeeEWKhanSRecent advances in transarterial embolotherapies in the treatment of hepatocellular carcinomaClin Mol Hepatol201723426527229113030
   PubMed Web of Science ®Google Scholar
• ChoYYLeeMKimHCRadioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysisPLoS One2016115e154986
   PubMed Web of Science ®Google Scholar
• de la TorreMABuades-MateuJde La RosaPAA comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenibLiver Int20163681206121226910784
   PubMed Web of Science ®Google Scholar
• GramenziAGolfieriRMosconiCYttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysisLiver Int20153531036104724750853
   PubMed Web of Science ®Google Scholar